Treatment of hepatocellular carcinoma: beyond international guidelines
- 4 January 2016
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 36 (S1) , 124-129
Abstract
Treatment of hepatocellular carcinoma (HCC) is guided by the tumour stage. The Barcelona clinical liver cancer (BCLC) score endorsed by the European Society of the Liver EASL divides patients into five prognostic categories, each with a distinct treatment indication. Hepatic resection, orthotopic liver transplantation and percutaneous local ablation are strongly indicated in accurately selected patients with very early (BCLC 0) and early stage (BCLC A) tumours providing a survival rate of between 50 and 75% at year five. In patients with a large tumour burden such as those with intermediate stage BCLC B, repeated treatments with transarterial chemoembolization (TACE) are advocated with clinical benefits (from 16 to 22 months). Survival may also improve in patients who are in poor condition or who do not respond to TACE and those with an advanced HCC (BCLC C), following oral therapy with the multikinase inhibitor, sorafenib. However, most recommendations are based on uncontrolled studies and expert opinions rather than well‐designed controlled trials, and up to one‐third of patients do not fit recommendations because of advanced age, the presence of significant comorbidities or a strategic location of the nodule. For these patients, treatment of HCC beyond guidelines is often advocated.Keywords
This publication has 42 references indexed in Scilit:
- Hepatocellular carcinomaThe Lancet, 2012
- Current Strategy for Staging and Treatment: The BCLC Update and Future ProspectsSeminars in Liver Disease, 2010
- The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosisGut, 2009
- Natural History of Post-Liver Transplantation Hepatitis CLiver Transplantation, 2009
- Major achievements in hepatocellular carcinomaThe Lancet, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatology, 2006
- Management of Hepatocellular Carcinoma *Hepatology, 2005
- Early Hepatocellular Carcinoma and Dysplastic NodulesSeminars in Liver Disease, 2005
- Small Hepatocellular Carcinoma in Cirrhosis: Randomized Comparison of Radio-frequency Thermal Ablation versus Percutaneous Ethanol InjectionRadiology, 2003